Deal Watch: Takeda Seeks A Crescendo With Collaboration On New Type Of Cancer Compound

 
• By Joseph Haas and Jung Won Shin

AstraZeneca concludes week of four out-licensing transactions by selling US rights to Toprol XL to Aralez and ex-US rights to Rhinocort Aqua to J&J. Molecular Partners gets back rights to an IL-13/IL-17 inhibitor for pulmonary indications after a 2011 deal with Janssen unravels.

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy transactions that occurred between Oct. 1-10. Deal Watch is supported by deal intelligence from Strategic Transactions.

Takeda Pharmaceutical Co. Ltd. is laying the groundwork for new cancer developments with a pair of platform investments, with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.